With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.

This marks Celltrion’s second regulatory submission for an omalizumab biosimilar as the US formulation patent protecting originator Xolair is set to expire late next year.

Govorestat could soon be filed for a second indication after impressing as a potential treatment for SORD deficiency, one of the most common forms of recessive hereditary neuropathy for which there are no approved therapies.

Advanz has acquired exclusive rights to register and commercialize a Phase III candidate from Dimerix in multiple territories, alongside agreements with Kyowa Kirin, Bayer and GP Pharm.